Category: Psilocybin Rescheduling
-
From Cannabis to Psilocybin: What Schedule III Rescheduling for Cannabis Tells Us About the Road Ahead
The federal rescheduling of medical cannabis from Schedule I to Schedule III is the most consequential shift in U.S. controlled substance policy in over fifty years. For those building the infrastructure for legal psilocybin medicine, it is also the clearest map yet of where this field is headed. The banking barriers, insurance gaps, and tax…
-
The Executive Order on Psychedelic Medicine Is a Signal, Not a Solution. Here’s What Comes Next.
In April 2026, President Trump signed an executive order accelerating research and access to psychedelic therapies. For patients, advocates, and practitioners, it is the clearest federal signal yet that the landscape is shifting. But a signal is not a solution. Here is what the order actually does, what it leaves unresolved, and why the window…
-
Urgent Action on Psilocybin Petition
RE: Psilocybin Rescheduling Petition, Dr. Sunil Aggarwal, AIMS Institute Dear Assistant Administrator Prevoznik: This is in further follow up to your letter to Dr. Sunil Aggarwal of the AIMS Institute, dated February 3, 2025, addressing our February 2, 2022 petition to transfer psilocybin from schedule I to schedule II of the Controlled Substances Act. Pursuant…
-
Freedom to Heal Act
The Freedom to Heal Act “creates a narrowly tailored DEA registration process exclusively for physicians to treat Right to Try eligible patients in clinical settings with qualifying Schedule I investigational therapies — such as MDMA and psilocybin – without changing the underlying RTT law.” https://lnkd.in/gAmyJWfU It should be noted that DEA, all along, has had…
-
Fighting for Psilocybin Access: Inside the Right-to-Try and Rescheduling Effort
As co-counsel in the federal psilocybin rescheduling case, Kathryn Tucker has witnessed firsthand the challenges, and opportunities in reforming outdated drug policy. In this conversation with Psychedelics Today, she shares the inside story of our legal strategy, the role of the Right to Try Act, and what rescheduling could mean for patients, providers, and the…
-
Psilocybin Rescheduling
In the ongoing battle to enable access to psilocybin assisted therapy, a significant effort is focused on moving it off Schedule I of the Controlled Substances Act, which severely restricts its use to research purposes only. In February 2022, we collaborated with Dr. Aggarwal to petition the Drug Enforcement Administration (DEA) to reschedule psilocybin to…
-
Update re AIMS et al. v. DEA: DEA Doubles Down in Denying Dying Patients Access to Psilocybin
In January 2021, Dr. Sunil Aggarwal, a respected palliative care physician and founder of the Advanced Integrative Medical Science (“AIMS”) Institute in Seattle, sought authorization from the DEA to obtain psilocybin for therapeutic use with his dying cancer patients. Psilocybin is an investigational drug shown to be remarkably effective in relieving debilitating anxiety and depression…
-
Landmark Petition to Reschedule Psilocybin filed with DEA
Bipartisan Congressional support for allowing terminal patients to seek relief from anxiety and depression in alignment with ongoing international research on the effectiveness of psilocybin in mental health care Statement Following issuance of the Ninth Circuit’s opinion in AIMS v DEA on Monday, January 31, 2022, finding lack of jurisdiction to review the DEA’s refusal…
-
Ninth Circuit ducks merits in nation’s first legal challenge to allow access to psilocybin in end-of-life care under “Right-To-Try” laws
Bipartisan Congressional support for allowing terminal patients to seek relief from anxiety and depression in alignment with ongoing international research on the effectiveness of psilocybin in mental health care Statement The Ninth Circuit’s opinion today, January 31, 2022, finding that the agency action in this matter was not final – “the DEA’s response letter was…
